Drugs / LB-P8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05053165 | Jan → Apr 2022 | metabolic dysfunction-associated steatohepatitis, rheumatoid arthritis | LISCure Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06699121 | Nov 2025 → Mar 2028 expected | primary sclerosing cholangitis | LISCure Biosciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-P8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05053165 ↗ |
| Route | Oral | “Healthy subjects will be randomized to receive LB-P8 once daily orally” NCT05053165 ↗ |